Newer P2Y12 Inhibitors: How Does the Interventional Cardiologist Choose?
Division of Cardiovascular Medicine, University of Southern California Los Angeles, CA shavelle@usc.edu.
David M
DM
Shavelle
Editorials; acute coronary syndrome; antiplatelet agents; antiplatelet drug; percutaneous coronary intervention
Am Heart J. 2016 Jun;176:44-52
27264219
Eur Heart J Cardiovasc Pharmacother. 2016 Jul;2(3):152-67
27533757
Curr Med Res Opin. 2015 Dec;31(12):2313-23
26402735
J Am Heart Assoc. 2016 Sep 23;5(9):null
27663414
N Engl J Med. 2009 Sep 10;361(11):1045-57
19717846
Cardiology. 2017;136(1):21-28
27548273
Nat Rev Cardiol. 2016 Jan;13(1):11-27
26283269
Circ Cardiovasc Qual Outcomes. 2013 May 1;6(3):293-8
23674313
Am Heart J. 2011 Nov;162(5):844-51
22093200
Am Heart J. 2016 Sep;179:10-8
27595675
Circulation. 2012 Sep 11;126(11):1345-54
22874581
N Engl J Med. 2007 Nov 15;357(20):2001-15
17982182
Eur Heart J Cardiovasc Pharmacother. 2016 Oct;2(4):229-43
27533946